Holen Sie sich die Stockscreener-App
0.5278
3.61%
0.0184
Handel nachbörslich:
.53
0.0022
+0.42%
Unicycive Therapeutics Inc Aktie (UNCY) Neueste Nachrichten
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Unicycive Therapeutics to Participate in Two Upcoming - GlobeNewswire
Unicycive Therapeutics CEO to Present at Noble Capital and Piper Sandler Healthcare Conferences | UNCY Stock News - StockTitan
Logos Global Management LP Adjusts Stake in Unicycive Therapeuti - GuruFocus.com
RA Capital Management's Strategic Acquisition of Unicycive Thera - GuruFocus.com
Great Point Partners LLC's Strategic Investment in Unicycive The - GuruFocus.com
Walleye Capital LLC Acquires New Stake in Unicycive Therapeutics Inc - GuruFocus.com
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Unicycive's OLC Drug Gets FDA Review Date, Reports Strong Q3 Pipeline Progress | UNCY Stock News - StockTitan
USFDA accepts Shilpa Medicare CDMO partner Unicycive NDA for Oxylanthanum Carbonate - Medical Dialogues
Unicycive Therapeutics (NASDAQ:UNCY) Given Buy Rating at HC Wainwright - MarketBeat
Unicycive shares hold as FDA accepts NDA for kidney treatment By Investing.com - Investing.com UK
Shilpa Medicare update on its CDMO partnerUnicycive Therapeutics - Business Standard
Unicycive shares hold as FDA reviews new drug application By Investing.com - Investing.com UK
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - Marketscreener.com
Unicycive eyes June FDA verdict for hyperphosphataemia drug - pharmaphorum
Unicycive: FDA to Review Lead Drug Candidate for Hyperphosphatemia - MarketWatch
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - The Manila Times
Unicycive Therapeutics Announces U.S. FDA Acceptance of the - GlobeNewswire
Unicycive's Kidney Disease Drug Gets FDA Review Date, Aims for 2025 Launch | UNCY Stock News - StockTitan
Thinking about buying stock in Beyondspring, LAVA Therapeutics, - GuruFocus.com
Unicycive Therapeutics Delivers Multiple Poster - GlobeNewswire
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 - GlobeNewswire
Unicycive Therapeutics to Participate in a Fireside Chat at - GlobeNewswire
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024 - StockTitan
This trade activity should not be overlooked: Unicycive Therapeutics Inc (UNCY) - SETE News
Unicycive Therapeutics, Inc. (NASDAQ:UNCY): Is Breakeven Near? - Simply Wall St
A year in review: Unicycive Therapeutics Inc (UNCY)’s performance in the last year - US Post News
Unicycive to present kidney disease therapies at ASN Kidney Week - Investing.com
Unicycive Therapeutics Inc’s Market Journey: Closing Strong at 0.37, Up 3.12 - The Dwinnex
Unicycive to present kidney disease therapies at ASN Kidney Week By Investing.com - Investing.com South Africa
UNCYUnicycive Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Unicycive Therapeutics Announces Late-Breaker Poster - GlobeNewswire
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024 - Yahoo Finance
Unicycive Therapeutics (UNCY) Price Target Increased by 21.14% to 5.41 - MSN
Octagon Capital Advisors LP Acquires New Stake in Unicycive Therapeutics Inc - Yahoo Finance
Octagon Capital Advisors LP Acquires New Stake in Unicycive Ther - GuruFocus.com
H.C. Wainwright & Co. Shares Buy Rating on Biotech Co. - Streetwise Reports
Unicycive reports successful phase 1 kidney drug trial - Investing.com
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers - The Manila Times
Unicycive reports successful phase 1 kidney drug trial By Investing.com - Investing.com UK
Unicycive Therapeutics Inc (UNCY) is looking forward to a strong quarter - SETE News
UNCY’s earnings forecast for the current quarter - US Post News
Ratio Analysis: Unpacking Unicycive Therapeutics Inc (UNCY)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Unicycive Therapeutics Inc: Weathering Stock Market Storms with 35.62M Market Cap - The InvestChronicle
Get in on Unicycive Therapeutics Inc’s (UNCY) buy-in window today! - SETE News
Unicycive Therapeutics' SWOT analysis: stock potential in kidney disease market - Investing.com
Was anything positive for Unicycive Therapeutics Inc (UNCY) stock last session? - US Post News
What is Unicycive Therapeutics Inc (UNCY) Stock Return on Shareholders’ Capital? - SETE News
Market Recap Check: Unicycive Therapeutics Inc (UNCY)’s Positive Finish at 0.44, Up/Down 2.82 - The Dwinnex
Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - ForexTV.com
Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor - EIN News
Unicycive Therapeutics Inc (UNCY) deserves closer scrutiny - US Post News
0.93%
3.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):